RECURSION PHARMACEUTICALS, INC. Defined Contribution Plan, Employer Matching Contribution, Percent of Match
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Defined Contribution Plan, Employer Matching Contribution, Percent of Match of 100.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Compensation Related Costs › Defined Contribution Plan
us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch · last filed 2026-02-25
- RECURSION PHARMACEUTICALS, INC. defined contribution plan, employer matching contribution, percent of match for the quarter ending 2021-03-31 was 100.00%.
- RECURSION PHARMACEUTICALS, INC. defined contribution plan, employer matching contribution, percent of match for fiscal 2025 was 100.00%, a 0.00% change from fiscal 2024.
- RECURSION PHARMACEUTICALS, INC. defined contribution plan, employer matching contribution, percent of match for fiscal 2024 was 100.00%, a 0.00% change from fiscal 2023.
- RECURSION PHARMACEUTICALS, INC. defined contribution plan, employer matching contribution, percent of match for fiscal 2023 was 100.00%, a 0.00% change from fiscal 2022.
- RECURSION PHARMACEUTICALS, INC. defined contribution plan, employer matching contribution, percent of match for fiscal 2022 was 100.00%, a 0.00% change from fiscal 2021.
| Period end | Defined Contribution Plan, Employer Matching Contribution, Percent of Match 3 month | Defined Contribution Plan, Employer Matching Contribution, Percent of Match 6 month | Defined Contribution Plan, Employer Matching Contribution, Percent of Match 12 month |
|---|---|---|---|
| 2025-12-31 | 100.00% 10-K · filed 2026-02-25 | ||
| 2024-12-31 | 100.00% 10-K · filed 2025-02-28 | ||
| 2023-12-31 | 100.00% 10-K · filed 2024-02-29 | ||
| 2022-12-31 | 100.00% 10-K · filed 2023-02-27 | ||
| 2021-12-31 | 100.00% 10-K · filed 2022-03-23 | ||
| 2021-06-30 | 100.00% 10-Q · filed 2021-08-13 | ||
| 2021-03-31 | 100.00% 10-Q · filed 2021-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |